When women think about hormone replacement therapy, estrogen dominates the conversation. And while estrogen is critically important, focusing on it exclusively leaves out a hormone that’s equally vital for women’s health and quality of life: testosterone.
Yes, testosterone. It’s not just a male hormone. Women produce testosterone in the ovaries and adrenal glands, and it plays essential roles in female physiology — roles that become painfully apparent when levels decline.
By menopause, a woman’s testosterone level is approximately 50% of what it was in her 20s. This decline contributes to symptoms that estrogen replacement alone doesn’t fully address: low libido, fatigue, loss of muscle mass, brain fog, and diminished sense of well-being. Yet most HRT programs — including those offered by competitors like Hims, Willow, and Pomegranate — focus almost exclusively on estrogen.
Luvo’s hormone replacement program recognizes testosterone as a critical component of comprehensive HRT, offering it in three formulations: injection, tablets, and gel.
Testosterone’s effects in women are wide-ranging and clinically significant.
Sexual desire and arousal are directly influenced by testosterone. It’s the primary hormone driving libido in women, acting on androgen receptors in the brain that regulate sexual motivation and pleasure. The decline in sexual desire that many women experience during and after menopause correlates closely with falling testosterone levels — and often doesn’t respond to estrogen therapy alone.
Energy and vitality are supported by testosterone’s effects on mitochondrial function, red blood cell production, and overall metabolic rate. Women with low testosterone frequently report a pervasive lack of energy that goes beyond what sleep and lifestyle adjustments can fix.
Muscle mass and bone density are maintained partly through testosterone’s anabolic effects. While estrogen gets most of the attention for bone health, testosterone contributes significantly to both bone mineralization and muscle protein synthesis. The loss of lean mass and increasing frailty in postmenopausal women is driven by declines in both hormones.
Cognitive function benefits from testosterone’s effects on brain health. Androgen receptors are distributed throughout the brain, and testosterone influences mood, mental clarity, memory, and cognitive processing speed.
Mood and well-being are affected in ways that overlap with but are distinct from estrogen’s effects. Many women describe testosterone’s impact as a restored sense of confidence, assertiveness, and general vitality that estrogen alone doesn’t provide.
Testosterone dosing for women is fundamentally different from men — women need approximately one-tenth the dose. Luvo’s formulations are specifically designed for female physiology.
Testosterone injection offers precise dosing and consistent absorption. Injections are administered on a regular schedule (often weekly or biweekly) and provide reliable blood levels. This option suits women who want the most controlled delivery and are comfortable with injection.
Testosterone tablets provide an oral option for women who prefer not to use topicals or injections. Oral testosterone for women is dosed carefully to achieve physiological female levels without exceeding the appropriate range.
Testosterone gel is applied topically in small amounts, typically to the inner arm or thigh. The gel absorbs through the skin and provides a steady testosterone delivery. Many women find this the most convenient and easiest option to incorporate into their daily routine.
Your Luvo provider will recommend the formulation and dose that best suits your hormonal profile, symptoms, and preferences. Explore each option: testosterone injection, testosterone tablets, and testosterone gel.
The use of testosterone in women is supported by a growing body of clinical evidence.
A landmark systematic review and meta-analysis published in The Lancet Diabetes and Endocrinology in 2019, analyzing 46 randomized controlled trials, found that testosterone therapy in women significantly improved sexual function, including desire, arousal, orgasm, and satisfaction. The benefits were consistent across postmenopausal women whether or not they were also taking estrogen.
The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published in 2019 and endorsed by multiple international medical societies, concluded that testosterone therapy at physiological female doses is effective for hypoactive sexual desire disorder in postmenopausal women and is associated with a favorable safety profile.
Emerging evidence also supports benefits for bone density, muscle mass, and cognitive function, though these indications are still under investigation.
The safety profile at appropriate female doses is reassuring. Common side effects are mild and dose-dependent, including acne, increased body hair, and oily skin. These are generally manageable with dose adjustment. Serious adverse effects are rare at physiological replacement doses.
Despite the evidence, testosterone remains conspicuously absent from most women’s HRT programs. There are several reasons for this gap.
Regulatory gaps mean there is no FDA-approved testosterone product specifically for women in the United States. This doesn’t mean testosterone for women is inappropriate — it means providers must prescribe compounded formulations or use male-approved products at adjusted doses. This requires more clinical expertise and comfort with off-label prescribing.
Outdated attitudes persist among some providers who associate testosterone exclusively with male health and are hesitant to prescribe it for women. The clinical evidence has moved far ahead of this attitude, but it remains a barrier to access.
Simplistic program design at many telehealth competitors means they offer estrogen and perhaps progesterone, but stop there. Adding testosterone requires additional clinical sophistication, monitoring, and formulation options that simpler programs aren’t set up to provide.
Luvo’s hormone replacement program is designed to provide the complete hormonal picture. For many women, adding testosterone to their estradiol regimen is the intervention that transforms their HRT experience from adequate to truly life-changing.
Visit Luvo’s hormone replacement program to discuss whether testosterone should be part of your protocol.
The Women’s Health Initiative (WHI) study, published in 2002, is the most influential — and most misunderstood — study in the history of hormone replacement therapy. Its initial results, which were widely reported as showing that HRT causes breast cancer and heart disease, led to millions of women abruptly stopping treatment and a generation of providers becoming afraid to prescribe it.
The human cost of this overreaction has been enormous. Women suffered through severe menopause symptoms unnecessarily. Rates of osteoporotic fractures increased. The gap between what the evidence actually shows and what many women (and some providers) believe about HRT remains one of the biggest failures of medical communication in modern history.
This article provides a clear, evidence-based assessment of what we actually know about HRT safety in 2026.
The WHI studied two specific regimens: oral conjugated equine estrogens (Premarin) plus medroxyprogesterone acetate (Provera) in women with a uterus, and Premarin alone in women who’d had a hysterectomy.
The estrogen-only arm actually showed a decreased risk of breast cancer and no increased cardiovascular risk. It was stopped early simply because it was part of the same administrative trial as the combination arm.
The combination arm showed a small increased risk of breast cancer (8 additional cases per 10,000 women per year) and a small increased risk of cardiovascular events. However, these risks were concentrated in women who started HRT more than 10 years after menopause and were over age 60 — a population very different from the typical woman who begins HRT in her early 50s.
Critically, the WHI used oral conjugated equine estrogens (derived from horse urine, containing multiple estrogen compounds) and a synthetic progestin (medroxyprogesterone acetate) — not the bioidentical estradiol and micronized progesterone that modern HRT typically uses. Subsequent research has shown that bioidentical formulations and transdermal delivery have substantially different risk profiles.
Breast cancer risk with modern HRT is more nuanced than headlines suggest. Estrogen-only therapy does not increase breast cancer risk and may reduce it. The combination of estrogen plus micronized progesterone (the bioidentical progestogen) appears to carry less breast cancer risk than the synthetic progestins used in the WHI. When risk does exist, it’s small in absolute terms and similar to risks associated with common lifestyle factors like alcohol consumption, obesity, and sedentary behavior.
Cardiovascular risk depends heavily on timing. The “timing hypothesis” is now well-established: women who start HRT within 10 years of menopause or before age 60 show neutral or even beneficial cardiovascular effects. Women who start HRT later may face increased risk. This window of opportunity is a key consideration in Luvo’s prescribing approach.
Venous thromboembolism (blood clot) risk is increased with oral estrogen but not with transdermal estrogen. This is one of the most clinically actionable findings in modern HRT research — and it’s why Luvo offers transdermal options (cream and patches) alongside tablets.
Stroke risk shows a similar pattern to clotting risk: modestly increased with oral estrogen, not increased with transdermal delivery, and dose-dependent. Using the lowest effective dose and transdermal delivery minimizes this concern.
Luvo’s hormone replacement program is designed with risk minimization built into every level.
Formulation selection matters. Luvo uses bioidentical estradiol, not conjugated equine estrogens. The availability of transdermal options (cream and patches) allows women with clotting risk factors to avoid oral estrogen entirely.
Route-of-delivery matching means your provider recommends the delivery method based on your risk profile, not just convenience. Women with elevated thrombotic risk are guided toward transdermal options. Women with predominantly vaginal symptoms may use localized therapy with minimal systemic exposure.
Non-hormonal alternatives ensure that women who cannot safely use estrogen still have effective treatment options. Paroxetine and Desvenlafaxine provide meaningful relief without any hormonal exposure.
Timing considerations are respected. Luvo’s providers follow the evidence-based window of opportunity, recommending HRT initiation for appropriate candidates within 10 years of menopause onset.
Ongoing monitoring through regular follow-ups ensures that treatment remains appropriate and effective over time, with dose adjustments as needed.
This comprehensive, evidence-informed approach to risk management is what distinguishes Luvo from competitors that offer a limited menu of options with minimal clinical nuance. Explore the full hormone replacement program.
No two women experience menopause the same way. Some are primarily bothered by hot flashes. Others struggle most with vaginal dryness or painful sex. Some are blindsided by mood changes and cognitive fog. And many deal with multiple symptoms simultaneously, each requiring its own treatment consideration.
The problem with one-size-fits-all HRT programs is that they treat menopause as a single condition with a single solution. Luvo’s program takes a symptom-specific approach, matching treatments to what you’re actually experiencing. This guide maps common menopause symptoms to the Luvo medications most effective for each.
Vasomotor symptoms are the hallmark of menopause, affecting up to 80% of women. They’re caused by estrogen-withdrawal-driven instability in the hypothalamic thermoregulatory center.
First-line treatments from Luvo include systemic estradiol, which directly addresses the underlying estrogen deficit. Estradiol tablets, cream, or patches all effectively reduce hot flash frequency and severity, typically by 75–95%. Transdermal options (cream and patches) are preferred for women with clotting risk factors.
For women who cannot take estrogen, Paroxetine is the FDA-approved non-hormonal option, reducing hot flash frequency by 33–65%. Desvenlafaxine offers potentially greater reduction at 55–70% and the added benefit of norepinephrine activity for energy and mood.
Night sweats are essentially nocturnal hot flashes and respond to the same treatments. Because they disrupt sleep, addressing them often produces cascading improvements in daytime energy, mood, and cognitive function.
Genitourinary syndrome of menopause (GSM) is progressive and affects the majority of postmenopausal women.
Localized vaginal estradiol is the most direct and effective treatment. Luvo’s estradiol vaginal gel and vaginal tablets deliver estrogen directly to the affected tissues with minimal systemic absorption. Most women experience significant improvement within 2–4 weeks, with continued improvement over 3 months.
Systemic estradiol (tablets, cream, or patches) provides some vaginal benefit as well, but many women with GSM need the additional concentrated local therapy that vaginal formulations provide.
For women who cannot use any form of estrogen, regular use of vaginal moisturizers and lubricants combined with Paroxetine or Desvenlafaxine for any accompanying vasomotor symptoms is the recommended alternative approach.
Declining sexual desire is one of the most distressing menopause symptoms and one of the most undertreated. It has both estrogen and testosterone components.
Testosterone therapy is the most evidence-based treatment for hypoactive sexual desire in postmenopausal women. Luvo’s testosterone injection, tablets, or gel can be added to an estradiol regimen (or used alone) to address libido directly. The 2019 Lancet meta-analysis confirmed that testosterone significantly improves desire, arousal, orgasm, and satisfaction in postmenopausal women.
Estradiol addresses the physical component by improving vaginal health, lubrication, and comfort during intercourse. When sex is no longer painful (thanks to vaginal estradiol), desire often improves as well.
The combination of systemic estradiol plus vaginal estradiol plus testosterone addresses sexual dysfunction from every angle — hormonal drive, physical comfort, and tissue health. This comprehensive approach is one of Luvo’s key differentiators.
Mood symptoms during menopause are driven by multiple factors: estrogen’s effects on serotonin and other neurotransmitters, sleep disruption from night sweats, and the psychological impact of the transition itself.
Estradiol therapy often produces significant mood improvement, particularly when mood symptoms are clearly linked to the menopausal transition. Stabilizing estrogen levels helps stabilize the neurochemical environment.
Paroxetine and Desvenlafaxine address mood symptoms through direct serotonergic and noradrenergic mechanisms. For women whose mood symptoms are severe, these medications may be used alongside or instead of estradiol. Desvenlafaxine’s SNRI mechanism may be particularly effective for the combination of depression, fatigue, and hot flashes.
Testosterone can contribute to improved mood, confidence, and overall sense of well-being. It’s rarely used as a primary mood treatment but can provide meaningful benefit as part of a comprehensive protocol.
Cognitive changes, persistent fatigue, and loss of lean mass are increasingly recognized as significant menopause symptoms driven by both estrogen and testosterone decline.
Estradiol supports cognitive function through its effects on cerebral blood flow, synaptic plasticity, and neurotransmitter function. Many women report improved mental clarity within weeks of starting estradiol therapy.
Testosterone’s role in energy, cognitive sharpness, and muscle maintenance makes it a valuable addition for women experiencing these symptoms. The anabolic effects of testosterone help maintain the lean mass and metabolic rate that decline during menopause.
Desvenlafaxine’s norepinephrine activity can address fatigue and cognitive fog independently of hormonal mechanisms, making it useful either as a complement to HRT or as a standalone option.
Luvo’s program recognizes that these symptoms often require a multi-medication strategy. Your provider will build a protocol that addresses your complete symptom picture. Visit the hormone replacement program to get started.
Estradiol is the gold standard for hormone replacement — but how it’s delivered to your body is just as important as the hormone itself. Different delivery methods produce different blood-level patterns, carry different risk profiles, target different tissues, and fit different lifestyles.
Luvo’s hormone replacement program offers five distinct estradiol formulations — more than most competitors provide. This comprehensive comparison helps you understand how each works, what it’s best for, and how they can be combined for complete symptom management.
Three of Luvo’s estradiol options provide systemic delivery — meaning the estradiol enters your bloodstream and circulates throughout your body, reaching estrogen receptors in the brain, bones, cardiovascular system, and other tissues.
Estradiol tablets are taken orally once daily. The hormone is absorbed through the GI tract and undergoes first-pass liver metabolism. This hepatic processing increases the production of certain liver proteins, including clotting factors and SHBG. The advantages are simplicity and familiarity. The clinical consideration is a modestly increased risk of venous thromboembolism compared to transdermal delivery.
Estradiol cream is applied to the skin daily. It absorbs through the dermis directly into the bloodstream, bypassing the liver. This avoids the clotting factor increase associated with oral delivery. The cream offers flexible dosing and a safe thrombotic profile. The practical trade-off is a brief daily application routine.
Estradiol patches are applied to the skin and replaced once or twice weekly. Like cream, they deliver estradiol transdermally. The unique advantage of patches is exceptionally steady hormone levels — no daily peaks and troughs. They offer the most consistent delivery, the best thrombotic safety, and the lowest maintenance routine of any systemic option.
Two of Luvo’s estradiol options deliver the hormone directly to the vaginal and urogenital tissues, with minimal absorption into the systemic circulation.
Estradiol vaginal gel is applied intravaginally using a measured applicator. It distributes across the vaginal walls and provides concentrated estrogen to the tissue that needs it most. Vaginal gel is effective for treating vaginal dryness, painful intercourse, vaginal atrophy, and urinary symptoms.
Estradiol vaginal tablets are small tablets inserted vaginally. They dissolve in place and release estradiol locally. The tablet format is clean, precise, and mess-free. Like the gel, it effectively treats GSM symptoms.
Both vaginal formulations produce very low systemic estradiol levels — typically remaining within the normal postmenopausal range. This makes them appropriate for women who need localized therapy but want to avoid or minimize systemic estrogen exposure.
Many women benefit from using more than one estradiol formulation simultaneously. This isn’t over-treatment — it’s targeted treatment.
The most common combination is a systemic formulation (tablets, cream, or patches) for hot flashes, mood, sleep, and bone protection, plus a vaginal formulation (gel or tablets) for concentrated urogenital symptom relief. Systemic estradiol provides some benefit to vaginal tissues, but many women find it insufficient for significant GSM symptoms. Adding vaginal estradiol provides the concentrated local effect these tissues need.
Your Luvo provider designs the combination based on your specific symptom profile. A woman whose primary complaints are hot flashes and insomnia might start with patches alone. If vaginal dryness develops later, vaginal gel or tablets can be added without changing the systemic component.
This modular approach — building and adjusting a multi-formulation protocol over time — is one of the key advantages of Luvo’s 10-medication program.
Here’s a practical summary to aid your decision.
Estradiol tablets are best for women who want simple daily dosing and have no elevated clotting risk. Application is a daily pill with no skin considerations. They offer the most straightforward routine but do carry modestly elevated thrombotic risk.
Estradiol cream is best for women wanting transdermal safety with flexible dosing. Application is daily to the skin with a brief drying period. It offers good safety and dose adjustability.
Estradiol patches are best for women wanting the steadiest levels and lowest maintenance. Application is once or twice weekly to the skin. They offer the most consistent delivery and best thrombotic safety.
Estradiol vaginal gel is best for vaginal dryness and urogenital symptoms. Application is intravaginal with an applicator. It provides excellent localized therapy with minimal systemic absorption.
Estradiol vaginal tablets are best for the same symptoms as gel with a cleaner, more precise format. Application is a small tablet inserted vaginally. It provides the same targeted relief with less mess.
Explore each option in detail: estradiol tablets, estradiol cream, estradiol patches, estradiol vaginal gel, and estradiol vaginal tablets. Or visit Luvo’s hormone replacement program for a comprehensive evaluation.